First Hit

Previous Doc

Next Doc

Go to Doc#

Generate Collection

Print

L46: Entry 601 of 614

File: DWPI

Oct 27, 1997

DERWENT-ACC-NO: 1998-231205

DERWENT-WEEK: 199912

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Controlled release naproxen tablets - contain 3% hydroxypropyl-methylcellu-

lose and optionally lubricant

INVENTOR: SHERMAN, B C

PATENT-ASSIGNEE:

ASSIGNEE SHERMAN B C

CODE

SHERI

PRIORITY-DATA: 1996CA-2175091 (April 26, 1996)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE PAGES MAIN-IPC

CA 2175091 A October 27, 1997 E 011 A61K031/19

CA 2175091 C January 5, 1999 000 A61K031/19

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

CA 2175091A

April 26, 1996

1996CA-2175091

CA 2175091C

April 26, 1996

1996CA-2175091

INT-CL (IPC): A61 \underline{K} 9/22; A61 \underline{K} 31/19; A61 \underline{K} 47/38

ABSTRACTED-PUB-NO: CA 2175091A

BASIC-ABSTRACT:

A controlled release tablet for once-daily oral administration of naproxen comprises 3% hydroxypropylmethylcellulose (HPMC) with average molecular weight of 190000.

The composition preferably also contains 0.1 to 3% of a lubricant.

USE - Naproxen is a widely used antiinflammatory drug with analgesic and antipyretic properties and is used in the treatment of e.g. $\underline{\text{arthritis}}$ and dysmenorrhea.

ADVANTAGE - Controlled release formulations give better patient compliance and reduced fluctuation of plasma drug concentration. The tables have suitable drug release rate and hardness and only contain 3% expensive HPMC.